Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
In up to 25% of patients with acquired TTP, anti-ADAMTS13 antibodies are not identified, the mechanism resulting from ADAMTS13 deficiency remains unidentified (uTTP). In this study, we provide further insights on clinical presentation and outcome of uTTP. In patients with baseline undetectable anti-ADAMTS13 antibodies, usual features of iTTP (young age, cerebral involvement, severe thrombocytopenia) with no other associated context than a history of systemic autoimmune disease or pregnancy, should prompt to consider the diagnosis of iTTP.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12130786 | PMC |
| http://dx.doi.org/10.3324/haematol.2024.285391 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-ADAMTS13 Antibodies Trajectory is Associated With ADAMTS13 Recovery in Immune-Mediated TTP.
Am J Hematol
July 2025
Centre de Référence des Microangiopathies Thrombotiques, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Current triplet regimens associating therapeutic plasma exchange (TPE), immunosuppression with corticosteroids and rituximab, and caplacizumab have dramatically improved the outcome of immune-mediated thrombotic thrombocytopenic purpura (iTTP). However, nearly half of the patients require extended caplacizumab treatment (i.e.
View Article and Find Full Text PDFSystemic Lupus Erythematosus-Associated Thrombotic Thrombocytopenic Purpura: A Case Report.
Cureus
June 2025
Anesthesia and Critical Care, Mohammed VI University Hospital, Tangier, MAR.
Systemic lupus erythematosus-associated thrombotic thrombocytopenic purpura (SLE-TTP) is a rare but life-threatening condition that requires prompt recognition and treatment. We report a case of a patient with systemic lupus erythematosus (SLE) who presented with encephalopathy and was subsequently diagnosed with thrombotic thrombocytopenic purpura (TTP) based on ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin motifs 13) deficiency. The patient was successfully treated with plasmapheresis.
View Article and Find Full Text PDFPregnancy-related Thrombotic Microangiopathy has a spectrum of underlying causes.
Pregnancy Hypertens
June 2025
Department of Bacteriology and Immunology and Translational Immunology Research Program, Helsinki, Finland; Hospital District of Helsinki and Uusimaa (HUS) Diagnostic Center, (HUSLAB), Helsinki University Hospital Laboratory, Helsinki, Finland.
Objectives: Pregnancy-associated Thrombotic Microangiopathy (pTMA) encompasses disorders leading to significant maternal morbidity and mortality and risks to the newborn. The complement system plays a key role in TMA pathogenesis, with pregnancy triggering susceptibility in women. Due to its rarity, timely diagnosis and management of pTMA remain challenging.
View Article and Find Full Text PDFAnti-ADAMTS13 Autoantibodies in Immune-Mediated Thrombotic Thrombocytopenic Purpura.
Antibodies (Basel)
March 2025
Department of Pathology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Autoantibodies to ADAMTS13 are at the center of pathology of the immune-mediated thrombotic thrombocytopenic purpura. These autoantibodies can be either inhibitory (enzymatic function) or non-inhibitory, resulting in protein depletion. Under normal physiologic conditions, antibodies are generated in response to foreign antigens, which can include infectious agents; however, these antibodies may at times cross-react with self-epitopes.
View Article and Find Full Text PDFChallenges in managing iTTP: insights into ADAMTS13 inhibitor boosting during caplacizumab therapy.
Ann Hematol
March 2025
Department of Hematology, Nara Medical University, Kashihara, Nara, Japan.
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare but life-threatening disorder characterized by severe thrombocytopenia, hemolytic anemia, and end-organ ischemic damage. The introduction of caplacizumab, an anti-von Willebrand factor A1 nanobody, has revolutionized the treatment of patients with iTTP by preventing fatal thrombotic events and shortening the time to platelet normalization. Despite its benefits, caplacizumab does not address the challenge of anti-ADAMTS13 autoantibody production, posing a risk of ADAMTS13 inhibitor boosting and delayed recovery of ADAMTS13 activity.
View Article and Find Full Text PDF